Investment
Features
FeesSafety
Academy
More
Pluang+

Compare TransMedics Group Inc (TMDX) vs Tyson Foods, Inc. (TSN) Price & Performance

TransMedics Group IncTrade
Tyson Foods, Inc.Trade

Price performance (Past 24H)

Key statistics

TransMedics Group Inc vs Tyson Foods, Inc. — how do they compare? TransMedics Group Inc trades at $87.08 (market cap $3.10B), while Tyson Foods, Inc. trades at $56.59 (market cap $19.85B). The key difference: Tyson Foods, Inc. is far larger — about 6.4× TransMedics Group Inc's market cap, and Tyson Foods, Inc. pays a 3.62% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

TMDXTSN
Market Cap
$3.10B$19.85B
Sector
TechnologyConsumer Staples
52-Week High
$150.42$68.75
52-Week Low
$61.99$50.72
Enterprise Value
$3.49B$27.12B
Dividend Yield
3.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.

The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.

Tyson Foods, Inc.

Tyson Foods (TSN) trades at $55.97, down 2.08% on the day, amid a bearish technical signal and mixed quarterly performance. Recent Q3 2026 earnings of $0.99 per share beat estimates, but revenue and volumes declined year-over-year. The company maintains a strong cash flow from operations of $2.16B in 2025, though net income margins are thin at 1.03%. Analyst consensus is a Buy with a $68.50 price target, highlighting a potential 22% upside from current levels.

The outlook for TSN is cautiously optimistic, with valuation metrics like P/S of 0.36 and EV/EBITDA of 10.38 suggesting potential undervaluation. Key risks include persistent losses in the beef segment due to high cattle costs and competitive pressures. Investment opportunity lies in the strength of chicken and prepared foods divisions, supported by a stable dividend yield. Monitoring Q3 2026 earnings release and beef margin normalization is critical for future performance.

Returns comparison

Trailing returns across standard periods

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX

About Tyson Foods, Inc.

Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.

Read more on TSN